Guardian Pharmacy Services, Inc
GRDN
Positions held
Your positionsGRDN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Guardian Pharmacy Services operates in a growing healthcare sector, focusing on medical care facilities, which are increasingly essential as the population ages.
- In Q2 2026, Guardian reported a revenue increase of 5% compared to the previous quarter, reaching $351.768 million.
- The gross margin improved to 22.8% in Q2 2026, up from 22.7% in Q1 2026.
- Despite its growth, Guardian has a high trailing P/E ratio of 40.0, indicating that the stock may be overvalued compared to its earnings.
- In 2024, Guardian experienced a significant operating margin decline of -5.1%, leading to a net income loss of $87.287 million.
- The company's score indicates a neutral signal with a score of 14.00, reflecting mixed market trends and bearish indicators.
Fundamentals
| Market cap | $2.64B | Enterprise value | $2.60B | Trailing P/E | 40.39 | Forward P/E | 29.00 |
| PEG | — | Price / book | 10.73 | Beta | 0.02 | Dividend yield | 0.00% |
| Revenue growth | 2.2% | Earnings growth | 139.8% | Gross margin | 21.6% | Operating margin | 3.5% |
| Profit margin | 4.5% | ROE | 30.4% | ROA | 13.4% | Debt / equity | 0.15 |
| Current ratio | 1.65 | Free cash flow | $64.55M | Analyst recommendation | strong_buy | Mean target | $49.86 |
| 52w high | $48.33 | 52w low | $23.14 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $352M | $337M | $398M | $377M | $344M | — |
| Op margin | 5.9% | 5.3% | 7.7% | 4.3% | 3.7% | — |
| Net income | $21.9M | $13.3M | $20.9M | $9.8M | $9.0M | — |
| Gross margin | 22.8% | 22.7% | 21.5% | 19.8% | 19.8% | — |
| Gross profit | $80.0M | $76.3M | $85.5M | $74.7M | $68.1M | — |
| Operating income | $20.6M | $17.7M | $30.8M | $16.4M | $12.6M | — |
- Revenue +5% vs prior quarter ($352M vs $337M).
- Gross margin 22.8% (was 22.7% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.2B | $1.0B | $909M | — |
| Op margin | 5.0% | -5.1% | 3.9% | 5.7% | — |
| Net income | $49.2M | -$87.3M | $23.9M | $35.4M | — |
| Gross margin | 20.2% | 19.9% | 19.9% | 20.4% | — |
| Gross profit | $293M | $244M | $208M | $186M | — |
| Operating income | $72.7M | -$62.9M | $40.9M | $52.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Zacks.com featured highlights include CNXN, ECG, GRDN, EXPD and PBF
2026-09-28 · Bet on Winning DuPont Analysis & Pick 5 Top Stocks
2026-09-23 · KeyBanc Initiates Guardian Pharmacy Services at Overweight With $52 Price Target
2026-09-21 · Truist Raises Price Target on Guardian Pharmacy Services to $51 From $47, Keeps Buy Rating
2026-09-01 · Guardian Pharmacy Services Buys Assets From Nautilus Pharmacy
2026-09-01 · Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy
2026-08-19 · Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference
2026-08-13 · Guardian Pharmacy Services (GRDN) Q2 2026 Earnings Call Transcript
2026-08-09 · Guardian Pharmacy Services (GRDN) As Strong Results And Higher Outlook Recast The Valuation Story
2026-08-08 · Why Guardian Pharmacy Services (GRDN) Is Up 10.9% After Raising 2026 Revenue Guidance And Expanding Footprint
2026-08-08 · Guardian Pharmacy Services Q2 Earnings Call Highlights
2026-08-07 · Oppenheimer Adjusts PT on Guardian Pharmacy Services to $49 From $43, Maintains Outperform Rating
Price (daily)
Full chart · RSI · MACD · patterns